Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc.（DCPH）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · DCPH · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
20
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Deciphera Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
DCPH 季度内部人买卖趋势
DCPH 内幕交易卖出 · DCPH 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
DCPH 高管卖出股份 · DCPH 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 22, 2024 | Brightstar Associates LLC 10 percent owner | Other | 48,136 | $481 | Form 4 |
| Feb 15, 2024 | Sherman Matthew L EVP & Chief Medical Officer | Award | 17,275 | — | Form 4 |
| Feb 16, 2024 | Sherman Matthew L EVP & Chief Medical Officer | Sale | 2,615 | $41K | Form 4 |
| Feb 15, 2024 | Kelly Thomas Patrick CFO | Award | 17,275 | — | Form 4 |
| Feb 16, 2024 | Kelly Thomas Patrick CFO | Sale | 3,010 | $47K | Form 4 |
| Feb 15, 2024 | Pitman Jama SVP, Chief Development Officer | Award | 10,000 | — | Form 4 |
| Feb 16, 2024 | Pitman Jama SVP, Chief Development Officer | Sale | 2,267 | $35K | Form 4 |
| Feb 15, 2024 | Pitman Jama SVP, Chief Development Officer | Award | 9,725 | — | Form 4 |
| Feb 15, 2024 | Dhanak Dashyant EVP & Chief Scientific Officer | Award | 17,275 | — | Form 4 |
| Feb 15, 2024 | Martin Daniel C. Chief Commercial Officer | Award | 9,725 | — | Form 4 |
| Feb 16, 2024 | Martin Daniel C. Chief Commercial Officer | Sale | 2,267 | $35K | Form 4 |
| Feb 7, 2024 | Brightstar Associates LLC 10 percent owner | Other | 914,001 | $9K | Form 4 |
| Jan 16, 2024 | Sherman Matthew L EVP & Chief Medical Officer | Sale | 2,435 | $35K | Form 4 |
| Jan 16, 2024 | Pitman Jama SVP, Chief Development Officer | Sale | 1,624 | $23K | Form 4 |
| Jan 16, 2024 | Kelly Thomas Patrick CFO | Sale | 2,435 | $35K | Form 4 |
| Jan 16, 2024 | Martin Daniel C. Chief Commercial Officer | Sale | 1,624 | $23K | Form 4 |
| Dec 12, 2023 | Hoerter Steven L. President and CEO · Director | Award | 62,500 | — | Form 4 |
| Dec 13, 2023 | Hoerter Steven L. President and CEO · Director | Sale | 30,664 | $471K | Form 4 |
| Dec 12, 2023 | Kelly Thomas Patrick CFO | Award | 8,244 | — | Form 4 |
| Dec 13, 2023 | Kelly Thomas Patrick CFO | Sale | 2,792 | $43K | Form 4 |
| Dec 12, 2023 | Pitman Jama See Remarks | Award | 5,576 | — | Form 4 |
| Dec 13, 2023 | Pitman Jama See Remarks | Sale | 1,662 | $26K | Form 4 |
| Dec 12, 2023 | Martin Daniel C. Chief Commercial Officer | Award | 5,576 | — | Form 4 |
| Dec 13, 2023 | Martin Daniel C. Chief Commercial Officer | Sale | 1,727 | $27K | Form 4 |
| Dec 12, 2023 | Sherman Matthew L EVP & Chief Medical Officer | Award | 8,244 | — | Form 4 |
Sherman Matthew L
EVP & Chief Medical Officer
日期
Feb 16
股数
2,615
均价
$15.62
总金额
$41K
Sherman Matthew L
EVP & Chief Medical Officer
日期
Jan 16
股数
2,435
均价
$14.47
总金额
$35K
Hoerter Steven L.
President and CEO · Director
日期
Dec 13
股数
30,664
均价
$15.37
总金额
$471K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 DCPH 内幕交易
DCPH 内幕交易
Deciphera Pharmaceuticals, Inc.（DCPH）内幕交易数据来源于公司内部人（包括DCPH）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。DCPH内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Deciphera Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
DCPH 内幕交易 · 5个问题Deciphera Pharmaceuticals, Inc.（DCPH）的内部人包括高管和董事，如DCPH等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026